Full-Time

Marketing Commercialization Specialist-Remote within the US

Posted on 9/11/2026

Deadline 9/14/26
Varian

Varian

5,001-10,000 employees

Tech-enabled radiation oncology hardware and software

Compensation Overview

$70.6k - $97.1k/yr

+ Commission

Company Historically Provides H1B Sponsorship

Remote in USA

Remote

Bachelor's

Category
Growth & Marketing (1)
Required Skills
Product Management
Word/Pages/Docs
Marketing
Data Analysis
Excel/Numbers/Sheets

Get referred to Varian

See people who can refer or advise you

Requirements
  • A bachelor's degree in Marketing, Business, Communications, Healthcare Administration, or a related field is required.
  • At least 2 years of professional experience in product marketing, commercialization, business operations, sales support, or a related business function is required.
  • Experience developing business cases, commercialization plans, and go-to-market strategies to support product launches and business growth initiatives is required.
  • Proficiency with Microsoft Excel, PowerPoint, and Word is required, including the ability to analyze data and create executive-ready presentations and documentation.
  • Strong project management and organizational skills are required, with the ability to manage multiple priorities and deadlines simultaneously.
  • Excellent written, verbal, and presentation communication skills are required, with the ability to tailor messaging for diverse stakeholder audiences.
  • Demonstrated analytical and problem-solving capabilities are required, including the ability to translate data and customer feedback into actionable recommendations.
  • The candidate must be able to build relationships and collaborate effectively across cross-functional teams in a highly matrixed environment.
  • The candidate must be self-motivated, detail-oriented, and customer-focused, with the ability to navigate ambiguity and drive results with limited direction.
  • A strong sense of ownership and accountability is required, with a track record of executing projects to a high standard and delivering quality results in a fast-paced environment.
  • The candidate must be able to influence stakeholders, manage competing priorities, and maintain focus on business objectives in a dynamic and evolving business landscape.
  • The successful candidate must be able to work with controlled technology in accordance with United States export control law.
Responsibilities
  • Drive product commercialization initiatives by supporting new product launches and lifecycle management activities across the portfolio.
  • Develop commercial tools and resources, including pricing strategies, quoting guidance, terms and conditions, business cases, commercialization plans, and field-facing documentation that enable successful sales execution.
  • Partner with Product Management, Sales Operations, Marketing, Legal, and regional commercial teams to ensure launch readiness and successful market adoption.
  • Coordinate commercial readiness activities, including validating country clearances, market availability, regulatory requirements, and operational readiness.
  • Create sales enablement content such as presentations, training materials, frequently asked questions, field communications, and competitive positioning.
  • Serve as a commercialization advisor to regional stakeholders, bridging global strategy and market-specific needs to accelerate customer adoption and business growth.
  • Analyze commercial performance and customer feedback using data and market insights to identify trends, improve commercialization effectiveness, and recommend enhancements to products, pricing, or go-to-market strategies.
  • Manage multiple priorities simultaneously across several products, projects, and stakeholders while maintaining quality and execution standards.
  • Lead and influence without direct authority by bringing diverse teams together to solve complex business challenges and deliver commercialization milestones on time.

Varian, part of Siemens Healthineers, focuses on oncology by providing integrated radiation oncology solutions that combine software, hardware, patient data, and care teams. Its offerings include treatment-planning software, radiation therapy machines, and data-management systems that work together to enable precise cancer treatments. The company differentiates itself through an integrated platform approach and services like Oncology-as-a-Service (OaaS), which lets healthcare providers adopt advanced radiation oncology with ongoing service support rather than large upfront investments. Varian serves healthcare providers such as hospitals and cancer centers, helping them deliver coordinated care and improve patient outcomes. Its goal is to reduce the fear of cancer by using data and technology to support clinicians in delivering effective treatments.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Palo Alto, California

Founded

1948

Get referred to Varian

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • ARPA-H awarded Varian up to $60 million in April 2026 for FLASH-RT.
  • FDA cleared TrueBeam for osteoarthritis in March 2026, opening a non-cancer market.
  • Telix collaboration and 2026 AI approvals expand Varian's clinical and software pipeline.

What critics are saying

  • RaySearch enabled online adaptive TrueBeam workflows in Belgium in May 2026, eroding software differentiation.
  • Elekta still attacks Varian's lead in adaptive radiotherapy and premium MR-guided care.
  • If FLASH and non-oncology bets fail by 2028, Varian becomes a commoditized linear-accelerator vendor.

What makes Varian unique

  • Siemens Healthineers gives Varian imaging, radiotherapy, and capital-sales integration globally.
  • Varian's 2026 CE-marked Eclipse AI contouring deepens workflow lock-in across planning.
  • TrueBeam, Halcyon, and Ethos create an installed-base moat hospitals rarely replace.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Holidays

Health Insurance

Dental Insurance

Vision Insurance

Wellness Program

401(k) Retirement Plan

Growth & Insights and Company News

Headcount

6 month growth

5%

1 year growth

5%

2 year growth

5%
MEDQOR
Apr 30th, 2026
Siemens Healthineers secures $83M to develop photon Flash radiotherapy for cancer treatment

Siemens Healthineers has received up to $60 million from the US Advanced Research Projects Agency for Health to develop photon Flash radiotherapy, with the company contributing an additional $23 million, totalling $83 million over five years. Flash photon therapy delivers radiotherapy more than 100 times faster than current technologies, aiming to reduce side effects and improve healthy tissue sparing. Unlike proton and electron beam platforms, which face scalability challenges, photon beams are the standard of care for over 50% of cancer patients. The project will build on existing C-arm linear accelerators to enable broader clinical access. Siemens Healthineers aims to transition ultra-high dose rate radiotherapy from experimental treatment into global standard of care within the five-year timeframe.

Business Wire
Mar 19th, 2026
Varian TrueBeam gets FDA clearance for low-dose radiotherapy to treat osteoarthritis

Siemens Healthineers has received FDA 510(k) clearance for its Varian TrueBeam radiotherapy systems to treat medically refractory osteoarthritis in adults using low-dose radiation therapy. This marks the first expansion of Varian's radiotherapy platform beyond cancer care into chronic musculoskeletal conditions. Osteoarthritis affects over 33 million adults in the US and approximately 600 million globally. The clearance covers TrueBeam, TrueBeam STx, VitalBeam and Edge systems, offering patients with persistent pain a non-invasive outpatient treatment option that targets inflammation, reduces pain and improves joint function. The approval builds on Varian's previous regulatory clearances for non-oncological indications, including radiosurgery treatment for medically refractory essential tremor. The TrueBeam platform combines high-resolution imaging with precise dose control whilst maintaining streamlined clinical workflows.

AuntMinnieEurope.com
Dec 10th, 2025
Telix and Varian enter research collaboration

Telix and Varian enter research collaboration. Telix Pharmaceuticals and Siemens Healthineers' company Varian have agreed to develop novel clinical applications that combine Telix's theranostics products and Varian's external beam radiation therapy (EBRT) technology. The first area of focus will be in identifying opportunities to use Telix's prostate cancer PET imaging agents in selecting patients for EBRT, developing personalized treatment plans (particularly in the context of Varian's Ethos adaptive radiotherapy system), and monitoring responses to treatment, Telix said. The agreement supports both company-sponsored and investigator-led clinical studies. Varian is a key player in EBRT and working with the company will allow Telix to explore how theranostics can be used more effectively by radiation oncologists to enhance patient selection and deliver targeted treatment, Telix noted. I agree to receive marketing related digital communications about products, services, events and offers that may be relevant to my given user preferences and behavior. I agree to share my information with the sponsor. I have read and agree to the privacy policy & terms of service and wish to opt-in.

AuntMinnie.com
Mar 28th, 2025
Varian, Embolx sign image-guided microcatheter agreement

Siemens Healthineers company Varian has entered into a sales and marketing agreement with Embolx for its Sniper Balloon Occlusion Microcatheter.

PR Newswire
Jul 29th, 2024
Varian Announces Future-Focused, Integrated Microwave Ablation Ecosystem With Intelliblate

PALO ALTO, Calif., July 29, 2024 /PRNewswire/ -- Varian, a Siemens Healthineers company, announces receipt of 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its IntelliBlate microwave ablation system, intended for ablation of soft tissue. Designed to provide clinicians with greater predictability, precision, and control during their procedures, IntelliBlate serves as the cornerstone of a future-focused, integrated ecosystem for microwave ablation.IntelliBlate produces large, controlled spherical ablation zones for predictable treatment delivery. With the option to utilize a single or dual probes – each with linked or independent controls – IntelliBlate delivers the versatility to meet the unique clinical needs of each patient. Precision and control are amplified by the Ximitry probe, which enables innovative features such as Laser Disk Alignment and intuitive LED indicators.The compact, versatile design and intuitive interface of IntelliBlate delivers a portable and flexible system that reduces barriers for this important treatment method. Modular elements provide the flexibility for clinicians to expand their treatment capabilities to meet changing clinical demands, all while keeping control over operational efficiency throughout the ablation procedure."IntelliBlate combines the features our customers say are most important for an efficient, integrated solution to seek improved levels of performance in microwave ablation," says Dr